Study shows less than 0.1% of U.S. adolescents with private insurance received gender-affirming medications from 2018 to 2022.

A recent study in JAMA Pediatrics found that fewer than 0.1% of U.S. adolescents with private insurance received gender-affirming medications like puberty blockers or hormones from 2018 to 2022. The research analyzed insurance claims for over 5.1 million young patients aged 8 to 17, revealing that no transgender patients under 12 were given gender-affirming hormones. The study highlights limited access to this care, despite ongoing public debates and the support from major medical organizations. The U.S. Supreme Court is set to rule on related laws soon.

2 months ago
107 Articles